Exsera Announces SARS-CoV-2 IgG antibody Testing. We are honored to be part of a large collaborative effort on the University of Colorado Anschutz Medical Campus to develop a novel orthogonal dual antigen ELISA that test antibodies to a unique combination of antigens that results is 99.6% specificity. Learn more.
We specialize in esoteric testing in the fields of complement, nephrology, and autoimmunity. We use our niche testing to more accurately diagnose patients with orphan and rare diseases. We have expertise in hereditary angioedema, atypical hemolytic uremic syndrome, and C3 glomerulopathy testing. Let us work with you to move from questions to diagnosis.
We have years of experience supporting niche immunotox testing for non-clinical and clinical IND studies. We support GLP and GCP testing in the areas of complement and those inflammatory responses that often occur in response to large molecules and biologics. In addition, our experience in patient diagnostic and our background in complement makes us an excellent choice for complement related efficacy testing.
We can deploy our experience in diagnostics and regulated testing to bring your biomarker discovery to a sufficiently-validated point that it can used with confidence. Together we can transfer your assays from a research setting to a CAP/CLIA regulated environment, the next step from bench to bedside.
Because we do this testing every day, we can bring consistent and efficient results that can enhance your research. If you have a cohort of patients who need complement, autoimmune, or immunoinflammatory testing, let us be your partner in completing that work.